Mevalonate kinase deficiency: therapeutic targets, treatments, and outcomes

References

• Favier LA, Schulert GS. Mevalonate kinase deficiency: current perspectives. Appl Clin Genet. 2016;9:101–110.
   Google Scholar
• Ter Haar NM, Jeyaratnam J, Lachmann HJ, et al. The phenotype and genotype of mevalonate kinase deficiency: a series of 114 cases from the Eurofever registry. Arthritis Rheumatol. 2016;68:2795–2805.
   Google Scholar
• Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore). 1994;73:133–144.
   Google Scholar
• van der Hilst JC, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore). 2008;87:301–310.
   Google Scholar
• Stabile A, Compagnone A, Napodano S, et al. Mevalonate kinase genotype in children with recurrent fevers and high serum IgD level. Rheumatol Int. 2013;33:3039–3042.
   Google Scholar
• Balgobind B, Wittebol-Post D, Frenkel J. Retinitis pigmentosa in mevalonate kinase deficiency. J Inherit Metab Dis. 2005;28:1143–1145.
   Google Scholar
• Kellner U, Stöhr H, Weinitz S, et al. Mevalonate kinase deficiency associated with ataxia and retinitis pigmentosa in two brothers with MVK gene mutations. Ophthalmic Genet. 2017;1–5.
   Google Scholar
• Kallianidis AF, Ray A, Goudkade D, et al. Amyloid A amyloidosis secondary to hyper IgD syndrome and response to IL-1 blockage therapy. Neth J Med. 2016;74:43–46.
   Google Scholar
• Yel S, Gunduz Z, Bastug F, et al. Amyloidosis in a child with hyperimmunoglobulinemia D syndrome. Iran J Kidney Dis. 2013;7:70–72.
   Google Scholar
• Lane T, Loeffler JM, Rowczenio DM, et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum. 2013;65:1116–1121.
   Google Scholar
• Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J. 2016;14:30.
   Google Scholar
• Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis. 2006;1:13.
   Google Scholar
• Jeyaratnam J, Ter Haar NM, de Sain-van der Velden MG, et al. Diagnostic value of urinary mevalonic acid excretion in patients with a clinical suspicion of mevalonate kinase deficiency (MKD). JIMD Rep. 2016;27:33–38.
   Google Scholar
• Mulders-Manders CM, Simon A. Hyper-IgD syndrome/mevalonate kinase deficiency: what is new? Semin Immunopathol. 2015;37:371–376.
   Google Scholar
• Overed-Sayer CL, Mosedale DE, Goodall M, et al. Measurement of human serum IgD levels. Curr Protoc Immunol. 2009:85:2.9B.1-2.9B.7.
   Google Scholar
• Hoffmann G, Gibson KM, Brandt IK, et al. Mevalonic aciduria – an inborn error of cholesterol and nonsterol isoprene biosynthesis. N Engl J Med. 1986;314:1610–1614.
   Google Scholar
• Jo EK, Kim JK, Shin DM, et al. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13:148–159.
   Google Scholar
• Akula MK, Shi M, Jiang Z, et al. Control of the innate immune response by the mevalonate pathway. Nat Immunol. 2016;17:922–929.
   Google Scholar
• van der Burgh R, Nijhuis L, Pervolaraki K, et al. Defects in mitochondrial clearance predispose human monocytes to interleukin-1β hypersecretion. J Biol Chem. 2014;289:5000–5012.
   Google Scholar
• Frenkel J, Rijkers GT, Mandey SH, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 2002;46:2794–2803.
   Google Scholar
• Mandey SH, Kuijk LM, Frenkel J, et al. A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum. 2006;54:3690–3695.
   Google Scholar
• Drenth JP, Van Deuren M, van der Ven-Jongekrijg J, et al. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood. 1995;85:3586–3593.
   Google Scholar
• Meyer-Hoffert U. Neutrophil-derived serine proteases modulate innate immune responses. Front Biosci (Landmark Ed). 2009;14:3409–3418.
   Google Scholar
• Weigert A, Jennewein C, Brüne B. The liaison between apoptotic cells and macrophages – the end programs the beginning. Biol Chem. 2009;390:379–390.
   Google Scholar
• Stoffels M, Jongekrijg J, Remijn T, et al. TLR2/TLR4-dependent exaggerated cytokine production in hyperimmunoglobulinaemia D and periodic fever syndrome. Rheumatology (Oxford). 2015;54:363–368.
   Google Scholar
• Fernandez-Ruiz I, Puchalska P, Narasimhulu CA, et al. Differential lipid metabolism in monocytes and macrophages: influence of cholesterol loading. J Lipid Res. 2016;57:574–586.
   Google Scholar
• Benarroch EE. Brain cholesterol metabolism and neurologic disease. Neurology. 2008;71:1368–1373.
   Google Scholar
• Bifulco M. Molecular mechanisms responsible for neuroinflammation and neurological impairments in mevalonate kinase deficiency. Mol Genet Metab Rep. 2015;3:42.
   Google Scholar
• Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015;6:254–264.
   Google Scholar
• Cartocci V, Servadio M, Trezza V, et al. Can cholesterol metabolism modulation affect brain function and behavior? J Cell Physiol. 2017;232:281–286.
   Google Scholar
• Bae SH, Lee JN, Fitzky BU, et al. Cholesterol biosynthesis from lanosterol. Molecular cloning, tissue distribution, expression, chromosomal localization, and regulation of rat 7-dehydrocholesterol reductase, a Smith-Lemli-Opitz syndrome-related protein. J Biol Chem. 1999;274:14624–14631.
   Google Scholar
• Hager EJ, Tse HM, Piganelli JD, et al. Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome. J Inherit Metab Dis. 2007;30:888–895.
   Google Scholar
• Celsi F, Piscianz E, Romano M, et al. Knockdown of MVK does not lead to changes in NALP3 expression or activation. J Inflamm (Lond). 2015;12:7.
   Google Scholar
• Simon A. Cholesterol metabolism and immunity. N Engl J Med. 2014 Nov;371(20):1933–1935.
   Google Scholar
• Marcuzzi A, Pontillo A, De Leo L, et al. Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. Pediatr Res. 2008;64:177–182.
   Google Scholar
• Marcuzzi A, Zanin V, Kleiner G, et al. Mouse model of mevalonate kinase deficiency: comparison of cytokine and chemokine profile with that of human patients. Pediatr Res. 2013;74:266–271.
   Google Scholar
• Tricarico PM, Piscianz E, Monasta L, et al. Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency. Apoptosis. 2015;20:1048–1055.
   Google Scholar
• Marcuzzi A, Piscianz E, Zweyer M, et al. Geranylgeraniol and neurological impairment: involvement of apoptosis and mitochondrial morphology. Int J Mol Sci. 2016;17:365.
   Google Scholar
• Platt FM, Wassif C, Colaco A, et al. Disorders of cholesterol metabolism and their unanticipated convergent mechanisms of disease. Annu Rev Genomics Hum Genet. 2014;15:173–194.
   Google Scholar
• Houten SM, Schneiders MS, Wanders RJ, et al. Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients. J Biol Chem. 2003;278:5736–5743.
   Google Scholar
• Waterham HR. Inherited disorders of cholesterol biosynthesis. Clin Genet. 2002;61:393–403.
   Google Scholar
• Houten SM, Koster J, Romeijn GJ, et al. Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome. Eur J Hum Genet. 2001;9:253–259.
   Google Scholar
• Muller AL, Freed DH. Basic and clinical observations of mevalonate depletion on the mevalonate signaling pathway. Curr Mol Pharmacol. 2017;10:6–12.
   Google Scholar
• van der Burgh R, Pervolaraki K, Turkenburg M, et al. Unprenylated RhoA contributes to IL-1β hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity. J Biol Chem. 2014;289:27757–27765.
   Google Scholar
• Henneman L, Schneiders MS, Turkenburg M, et al. Compromized geranylgeranylation of RhoA and Rac1 in mevalonate kinase deficiency. J Inherit Metab Dis. 2010;33:625–632.
   Google Scholar
• Agabiti SS, Liang Y, Wiemer AJ. Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation. Mol Membr Biol. 2016;33:1–11.
   Google Scholar
• Jurczyluk J, Munoz MA, Skinner OP, et al. Mevalonate kinase deficiency leads to decreased prenylation of Rab GTPases. Immunol Cell Biol. 2016;94:994–999.
   Google Scholar
• Hashemi M, Hoshyar R, Ande SR, et al. Mevalonate cascade and its regulation in cholesterol metabolism in different tissues in health and disease. Curr Mol Pharmacol. 2017;10:13–26.
   Google Scholar
• Bodar EJ, van der Hilst JC, Drenth JP, et al. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med. 2005;63:260–264.
   Google Scholar
• Marcuzzi A, Piscianz E, Valencic E, et al. To extinguish the fire from outside the cell or to shutdown the gas valve inside? Novel trends in anti-inflammatory therapies. Int J Mol Sci. 2015;16:21277–21293.
   Google Scholar
• Liao P, Hemmerlin A, Bach TJ, et al. The potential of the mevalonate pathway for enhanced isoprenoid production. Biotechnol Adv. 2016;34:697–713.
   Google Scholar
• Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19:107–120.
   Google Scholar
• Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 2000;5:415–418.
   Google Scholar
• Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. J Pharmacol Exp Ther. 2012;342:619–630.
   Google Scholar
• Qian Y, Cao L, Guan T, et al. Protection by genistein on cortical neurons against oxidative stress injury via inhibition of NF-kappaB, JNK and ERK signaling pathway. Pharm Biol. 2015;53:1124–1132.
   Google Scholar
• Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35–46.
   Google Scholar
• Lappano R, Recchia AG, De Francesco EM, et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. Plos One. 2011;6:e16631.
   Google Scholar
• Olsen BN, Schlesinger PH, Ory DS, et al. 25-Hydroxycholesterol increases the availability of cholesterol in phospholipid membranes. Biophys J. 2011;100:948–956.
   Google Scholar
• Diczfalusy U. On the formation and possible biological role of 25-hydroxycholesterol. Biochimie. 2013;95:455–460.
   Google Scholar
• Bauman DR, Bitmansour AD, McDonald JG, et al. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Proc Natl Acad Sci USA. 2009;106:16764–16769.
   Google Scholar
• Cyster JG, Dang EV, Reboldi A, et al. 25-Hydroxycholesterols in innate and adaptive immunity. Nat Rev Immunol. 2014;14:731–743.
   Google Scholar
• Jang J, Park S, Jin Hur H, et al. 25-hydroxycholesterol contributes to cerebral inflammation of X-linked adrenoleukodystrophy through activation of the NLRP3 inflammasome. Nat Commun. 2016;7:13129.
   Google Scholar
• Coward WR, Marei A, Yang A, et al. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol. 2006;176:5284–5292.
   Google Scholar
• Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf. 2012;11:933–946.
   Google Scholar
• Attout H, Guez S, Ranaivo I, et al. A patient with hyper-IgD syndrome responding to simvastatin treatment. Eur J Intern Med. 2008;19:e82–3.
   Google Scholar
• Kuijk LM, Mandey SH, Schellens I, et al. Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Mol Immunol. 2008;45:2158–2165.
   Google Scholar
• Simon A, Drewe E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther. 2004;75:476–483.
   Google Scholar
• Houten SM, Frenkel J, Rijkers GT, et al. Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet. 2002;11:3115–3124.
   Google Scholar
• Zanin V, Marcuzzi A, Kleiner G, et al. Lovastatin dose-dependently potentiates the pro-inflammatory activity of lipopolysaccharide both in vitro and in vivo. J Cardiovasc Transl Res. 2013;6:981–988.
   Google Scholar
• Thurnher M, Gruenbacher G, Nussbaumer O. Regulation of mevalonate metabolism in cancer and immune cells. Biochim Biophys Acta. 2013;1831:1009–1015.
   Google Scholar
• Diel IJ, Bergner R, Grötz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol. 2007;5:475–482.
   Google Scholar
• Agrawal AG, Somani RR. Farnesyltransferase inhibitor as anticancer agent. Mini Rev Med Chem. 2009;9:638–652.
   Google Scholar
• Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 1987;41:326–331.
   Google Scholar
• Corrado A, Cantatore FP. The bisphosponates: chemical characteristics, skeletal biological effects and extra-skeletal effects. Reumatismo. 2005;57:142–153.
   Google Scholar
• Makkonen N, Salminen A, Rogers MJ, et al. Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. Eur J Pharm Sci. 1999;8:109–118.
   Google Scholar
• Maruyama N, Takizawa T, Ishibashi H, et al. Protective activity of geranium oil and its component, geraniol, in combination with vaginal washing against vaginal candidiasis in mice. Biol Pharm Bull. 2008;31:1501–1506.
   Google Scholar
• Ong TP, Heidor R, de Conti A, et al. Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis. 2006;27:1194–1203.
   Google Scholar
• Chang FY, Lu CL. Treatment of irritable bowel syndrome using complementary and alternative medicine. J Chin Med Assoc. 2009;72:294–300.
   Google Scholar
• Merat S, Khalili S, Mostajabi P, et al. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci. 2010;55:1385–1390.
   Google Scholar
• de Moura Espíndola R, Mazzantini RP, Ong TP, et al. Geranylgeraniol and beta-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-kappaB activation. Carcinogenesis. 2005;26:1091–1099.
   Google Scholar
• Peterson YK, Kelly P, Weinbaum CA, et al. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem. 2006;281:12445–12450.
   Google Scholar
• Lackner MR, Kindt RM, Carroll PM, et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell. 2005;7:325–336.
   Google Scholar
• Zhang FL, Fu HW, Casey PJ, et al. Substitution of cadmium for zinc in farnesyl: proteintransferase alters its substrate specificity. Biochemistry. 1996;35:8166–8171.
   Google Scholar
• Ichikawa M, Ohtsuka M, Ohki H, et al. Discovery of DF-461, a potent squalene synthase inhibitor. ACS Med Chem Lett. 2013;4:932–936.
   Google Scholar
• Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract. 2012;66:270–280.
   Google Scholar
• Bergstrom JD, Kurtz MM, Rew DJ, et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci USA. 1993;90:80–84.
   Google Scholar
• Bodar EJ, Kuijk LM, Drenth JP, et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis. 2011;70:2155–2158.
   Google Scholar
• Vitale A, Rigante D, Lucherini OM, et al. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm. 2013;2013:939847.
   Google Scholar
• Arkwright PD, Abinun M, Cant AJ. Mevalonic aciduria cured by bone marrow transplantation. N Engl J Med. 2007;357:1350.
   Google Scholar
• Neven B, Valayannopoulos V, Quartier P, et al. Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med. 2007;356:2700–2703.
   Google Scholar
• El-Sayyad HI. Cholesterol overload impairing cerebellar function: the promise of natural products. Nutrition. 2015;31:621–630.
   Google Scholar
• Lane KT, Beese LS. Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res. 2006;47:681–699.
   Google Scholar
• Suzuki N, Ito T, Matsui H, et al. Anti-inflammatory and cytoprotective effects of a squalene synthase inhibitor, TAK-475 active metabolite-I, in immune cells simulating mevalonate kinase deficiency (MKD)-like condition. Springerplus. 2016;5:1429.
   Google Scholar
• Ebihara T, Takeuchi T, Moriya Y, et al. Characterization of transporters in the hepatic uptake of TAK-475 M-I, a squalene synthase inhibitor, in rats and humans. Drug Res (Stuttg). 2016;66:316–323.
   Google Scholar
• Stein EA, Bays H, O’Brien D, et al. Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. Circulation. 2011;123:1974–1985.
   Google Scholar
• Liao JK. Squalene synthase inhibitor lapaquistat acetate: could anything be better than statins? Circulation. 2011;123:1925–1928.
   Google Scholar
• Seiki S, Frishman WH. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. Cardiol Rev. 2009;17:70–76.
   Google Scholar
• Davidson MH. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009;11:67–70.
   Google Scholar
• Cochemé HM, Kelso GF, James AM, et al. Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion. 2007;7(Suppl):S94–102.
   Google Scholar
• Dhanasekaran A, Kotamraju S, Kalivendi SV, et al. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem. 2004;279:37575–37587.
   Google Scholar